Compare Amphastar Pharmaceuticals Inc (AMPH) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Comcast Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Comcast Corporation trades at $23.6 (market cap $84.20B). The key difference: Comcast Corporation is far larger — about 101.9× Amphastar Pharmaceuticals Inc's market cap, and Comcast Corporation pays a 5.6% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CMCSA | |
|---|---|---|
Market Cap | $826.08M | $84.20B |
Sector | Health | Media |
52-Week High | $30.81 | $33.81 |
52-Week Low | $16.87 | $22.32 |
Enterprise Value | $1.22B | $169.34B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CMCSA trades at $23.57, up 0.96% with strong fundamentals including a low P/E of 4.62 and net income margin of 15%. Recent earnings beats and a $2.14B acquisition of ITV's media unit signal strategic growth. Technicals are bearish with support at $23, while analyst consensus remains bullish with a $30.94 price target.
Outlook: Undervalued with robust cash flow and dividend yield, but weighed by bearish technicals and spin-off uncertainty. Key risks include integration challenges from acquisitions and competitive pressures in media and broadband sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
